All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.
During the 8th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub was pleased to speak to Irene Ghobrial, Dana-Farber Cancer Institute, Boston, US. We asked, What have we learnt about monoclonal gammopathy of undetermined significance (MGUS) prevalence and clinical implications?
The PROMISE study: What have we learnt about MGUS prevalence and clinical implications?
Ghobrial begins by outlining the initial results of the PROMISE study, including the benefits of using mass spectrometry for identifying MGUS. Finally, Ghobrial discusses the overall survival and comorbidities that are associated with monoclonal gammopathies.
3 things to remember when diagnosing patients with MGUS
During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub spoke with Graham Jackson, Newcastle University, Newcastle upon Tyne, UK. He discusses three...
Updating the NCCN guidelines for the diagnosis and treatment of MGUS and SMM
During the National Comprehensive Cancer Network (NCCN) 2021 Annual Conference, the Mutiple Myeloma Hub spoke to Timothy M. Schmidt, University of Wisconsin-Madison,...
Defining the significance of MGUS: the bone marrow microenvironment is compromised from an early stage in MM
In a recent study, Oksana Zavidij from the Dana-Farber Cancer Institute and colleagues aimed to elucidate the transcriptomic alterations...
Subscribe to get the best content related to multiple myeloma delivered to your inbox